Evidence map›Paper›PMID 35720667›Full record

ArticleJBMR plus2022

Functional Properties of Two Distinct PTH1R Mutants Associated With Either Skeletal Defects or Pseudohypoparathyroidism.

Ignacio Portales-Castillo, Thomas Dean, Ashok Khatri, Harald Jüppner, Thomas J Gardella

Open access · goldAbstract read
In one paragraph

Article in JBMR plus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Eiken syndrome with parathyroid hormone resistance due to a novel parathyroid hormone receptor type 1 mutation: clinical features and functional analysis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2024
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ignacio Portales-CastilloDepartment of Medicine, Division of Nephrology Massachusetts General Hospital, and Harvard Medical School Boston MA USA.
Thomas DeanEndocrine Unit Massachusetts General Hospital, and Harvard Medical School Boston MA USA.
Ashok KhatriEndocrine Unit Massachusetts General Hospital, and Harvard Medical School Boston MA USA.
Harald JüppnerEndocrine Unit Massachusetts General Hospital, and Harvard Medical School Boston MA USA.
Thomas J GardellaEndocrine Unit Massachusetts General Hospital, and Harvard Medical School Boston MA USA.ORCID https://orcid.org/0000-0002-2163-5772
Harvard University · US

Funding

Tissue Phenotyping CoreP01DK011794 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BOUXSEIN, MARY L · 1986 to 2023
$44.4M
PTH/PTHRP RECEPTOR DEFECTS IN PSEUDOHYPOPARATHYROIDISMR01DK046718 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI JUEPPNER, HARALD W. · 1993 to 2024
$6.0M
Molecular Definition of PseudohypoparathyroidismR37DK046718 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI JUEPPNER, HARALD W. · 2002 to 2011
$4.0M
Molecular Definition of PseudohypoparathyroidismR56DK046718 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI JUEPPNER, HARALD W. · 2012 to 2012
$218k
NIDDK NIH HHS P01 DK011794NIDDK NIH HHS R01 DK046718NIDDK NIH HHS R37 DK046718NIDDK NIH HHS R56 DK046718
6 · The paper itself

Abstract

Consistent with a vital role of parathyroid hormone (PTH) receptor type 1 (PTH1R) in skeletal development, homozygous loss-of-function PTH1R mutations in humans results in neonatal lethality (Blomstrand chondrodysplasia), whereas such heterozygous mutations cause a primary failure of tooth eruption (PFE). Despite a key role of PTH1R in calcium and phosphate homeostasis, blood mineral ion levels are not altered in such cases of PFE. Recently, two nonlethal homozygous PTH1R mutations were identified in two unrelated families in which affected members exhibit either dental and skeletal abnormalities (PTH1R-V204E) or hypocalcemia and hyperphosphatemia (PTH1R-R186H). Arg186 and Val204 map to the first transmembrane helix of the PTH1R, and thus to a critical region of this class B G protein-coupled receptor. We used cell-based assays and PTH and PTH-related protein (PTHrP) ligand analogs to assess the impact of the R186H and V204E mutations on PTH1R function in vitro. In transiently transfected HEK293 cells, PTH1R-R186H mediated cyclic adenosine monophosphate (cAMP) responses to PTH(1-34) and PTHrP(1-36) that were of comparable potency to those observed on wild-type PTH1R (PTH1R-WT) (half maximal effective concentrations [EC50s] = 0.4nM to 1.2nM), whereas the response-maxima were significantly reduced for the PTH1R-V204E mutant (maximum effect [Emax] = 81%-77% of PTH1R-WT,

Indexed as

HYPERPHOSPHATEMIAHYPOCALCEMIAPARATHYROIDPRIMARY FAILURE OF TOOTH ERUPTIONPSEUDOHYPOPARATHYROIDISMPTHPTH1RPTHrP

Identifiers

PMID35720667
PMCPMC9189904
OpenAlexW4206754282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.